Clinical trials: Dosimetry
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Patients With Solid Tumors
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.
- Trial name
- NCT07070349
- Testing
- HRS-6213
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer, mCRPC
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of…
- Trial name
- NCT05547061
- Testing
- Lu-177-DGUL, Ga-68-NGUL
- Where
- 4 sites in South Korea
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Cellbion Co., Ltd.
Lymphoma, Non-Hodgkin
Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug acts in the body, on the cancer cells and how safe it is in patients with advanced non-Hodgkin's lymphoma (NHL)
- Trial name
- NCT02581878
- Testing
- BAY1862864
- Where
- 4 sites in Sweden, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Bayer
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers, Cancer Patients
Clinical Study of 18F-LNC1007 Injection PET/CT
This study is a single-arm, single-center trial aimed at evaluating the pharmacokinetics, bio-distribution, dosimetry, and safety of 18F-LNC1007 injection in healthy volunteers and light tumor burden cancer patients, as defined…
- Trial name
- NCT06471712
- Testing
- 18F-LNC1007 Injection
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Soft Tissue Sarcoma, PDGFR Alpha Positive Solid Tumours
89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue Sarcoma
Soft Tissue Sarcoma (STS) is a cancer of soft tissues that often expresses Platelet-Derived Growth Factor Receptor (PDGFR)α, a potential therapeutic target. PDGFRα is also found in other advanced solid tumours.
- Trial name
- ZOLAR (NCT06537596)
- Testing
- 89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617)…
- Trial name
- NCT06004661
- Testing
- AAA617, 68Ga-PSMA-11
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
This is an open-label, single dose study for patients 18 years of age or older with confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an injection of approximately 4.0 to 6.0 mCi (148-222 MBq)…
- Trial name
- NCT00747825
- Testing
- 131-I-MIP-1145
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Hepatocellular Carcinoma
A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC
This retrospective, multinational, single-arm study will be conducted in at least 8 sites. An interim analysis will be conducted with data from 100 patients with up to 10 well defined HCC tumor(s) and with at least one tumor ≥3…
- Trial name
- TARGET (NCT03295006)
- Testing
- TheraSphere
- Where
- 14 sites in United States, France and 6 more
- Volunteers
- 209 people
- Sponsor
- Boston Scientific Corporation
Neoplasms
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of [177Lu]-NeoB in patients with advanced solid tumors known to overexpress…
- Trial name
- NeoRay (NCT03872778)
- Testing
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 35 people
- Sponsor
- Advanced Accelerator Applications
Hepatocellular Carcinoma (HCC), Solid Tumors
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Researchers are studying a new potential treatment for liver cancer or other select solid cancers. To do this, researchers have developed a protein, called a monoclonal antibody, which can find and attach itself to another…
- Trial name
- NCT06345001
- Testing
- BAY3630942, BAY3547922
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Bayer
Healthy Adult
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
This is an open-label, single-center, phase 1 study to further characterize [18F]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study.
- Trial name
- NCT07617688
- Testing
- [¹⁸F]MODAG-009 PET Imaging
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Solid Tumor, Metastatic Cancer
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid…
- Conditions
- Solid Tumor, Metastatic Cancer, Unresectable Solid Tumor, Recurrent Solid Tumor
- Trial name
- Tumorad (NCT06184035)
- Testing
- [177Lu]Lu-SN201
- Where
- 2 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Spago Nanomedical AB
Pheochromocytoma, Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
- Trial name
- NCT00458952
- Testing
- Ultratrace Iobenguane (MIBG) I 131
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Heart Failure
A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure
The purpose of this clinical study is to estimate the safety and radiation dosimetry of a single dose of LMI1195 in healthy subjects and heart failure patients undergoing positron emission tomography (PET)
- Trial name
- NCT00891241
- Testing
- LMI 1195-101
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lantheus Medical Imaging
Prostate Cancer, Metastases
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
- Conditions
- Prostate Cancer, Metastases, Pharmacokinetics
- Trial name
- NCT00748046
- Testing
- Radium-223 chloride (BAY88-8223)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
The purpose of this study is to assess the safety and effectiveness of treating a tumor using a different planning method called MCD for the FDA-Approved device, TheraSphere.
- Trial name
- ADVANCE-MCD (NCT07669727)
- Testing
- TheraSphere
- Volunteers
- 140 people
- Sponsor
- Boston Scientific Corporation
Neoplasm
Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
This study is a visual assessment of diagnostic PET/CT images obtained after a single intravenous injection of BAY85-8050 in patients with cancer
- Trial name
- NCT00961831
- Testing
- F-18 (BAY85-8050)
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bayer